Royce & Associates’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-178,676
| Closed | -$7.34M | – | 948 |
|
|
2022
Q1 | $7.34M | Buy |
178,676
+2,120
| +1% | +$87K | 0.06% | 456 |
|
|
2021
Q4 | $7.68M | Sell |
176,556
-59,275
| -25% | -$2.58M | 0.06% | 461 |
|
|
2021
Q3 | $11.8M | Buy |
235,831
+941
| +0.4% | +$47.1K | 0.09% | 358 |
|
|
2021
Q2 | $14.8M | Sell |
234,890
-2,271
| -1% | -$143K | 0.1% | 337 |
|
|
2021
Q1 | $22M | Buy |
237,161
+53,579
| +29% | +$4.98M | 0.15% | 218 |
|
|
2020
Q4 | $16.4M | Buy |
183,582
+68,017
| +59% | +$6.09M | 0.14% | 227 |
|
|
2020
Q3 | $11.9M | Sell |
115,565
-63,429
| -35% | -$6.55M | 0.13% | 234 |
|
|
2020
Q2 | $14.2M | Sell |
178,994
-22,000
| -11% | -$1.74M | 0.16% | 176 |
|
|
2020
Q1 | $11.6M | Sell |
200,994
-115,933
| -37% | -$6.71M | 0.16% | 176 |
|
|
2019
Q4 | $17.1M | Buy |
316,927
+17,419
| +6% | +$940K | 0.15% | 179 |
|
|
2019
Q3 | $15.7M | Buy |
299,508
+58,644
| +24% | +$3.07M | 0.14% | 200 |
|
|
2019
Q2 | $11.6M | Buy |
240,864
+235,230
| +4,175% | +$11.4M | 0.11% | 281 |
|
|
2019
Q1 | $285K | Buy |
+5,634
| New | +$285K | ﹤0.01% | 973 |
|
|
2018
Q4 | – | Sell |
-559
| Closed | -$37K | – | 1164 |
|
|
2018
Q3 | $37K | Buy |
559
+195
| +54% | +$12.9K | ﹤0.01% | 1067 |
|
|
2018
Q2 | $18K | Buy |
364
+152
| +72% | +$7.52K | ﹤0.01% | 1140 |
|
|
2018
Q1 | $11K | Sell |
212
-20
| -9% | -$1.04K | ﹤0.01% | 1162 |
|
|
2017
Q4 | $11K | Sell |
232
-26
| -10% | -$1.23K | ﹤0.01% | 1165 |
|
|
2017
Q3 | $10K | Buy |
+258
| New | +$10K | ﹤0.01% | 1163 |
|
|
2013
Q3 | – | Sell |
-30,386
| Closed | -$438K | – | 1453 |
|
|
2013
Q2 | $438K | Buy |
+30,386
| New | +$438K | ﹤0.01% | 1244 |
|